Adipokines: role in local and systemic inflammation of rheumatic diseases

Šenolt, Ladislav

doi:10.1080/1744666x.2017.1249850

Cited by 14 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, by regulating the activity of Treg cells, leptin could be the bridge between immune tolerance, metabolic function and autoimmunity . It may also suggest that local regulation of adipokines by activated immune cells and resident in adipose tissue and/or synovial joints or periodontal tissue may contribute to the increase in systemic levels of some adipokines that may precede the development of RA or greater structural progression of RA …”

Section: Discussionmentioning

confidence: 99%

Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first‐degree relatives

et al. 2019

View full text Add to dashboard Cite

Objective:To evaluate the adipokine levels in early rheumatoid arthritis (eRA) and first-degree relatives (FDR) of patients with RA and establish their association with rheumatic disease activity and periodontal variables. Method:A cross-sectional study with eRA patients, FDR and a healthy population.Adipokine levels, clinical, joint radiological indexes and periodontal variables were evaluated. A descriptive, bivariate analysis was performed based on the adipokine levels by χ 2 , Fisher's test and Mann-Whitney U test. A logistic regression was made for associations. Results:High leptin levels were associated with the diagnosis of eRA (odds ratio[OR] = 2.79; 95% CI 1.54-5.07). Early rheumatoid arthritis with high adiponectin levels was less likely to have Multidimensional Health Assessment Questionnaire score >3, body mass index (BMI) >25 and Routine Assessment of Patient Index Data 3 score >12 (OR = 0.16; 95% CI 0.03-0.72). Early rheumatoid arthritis was more likely to present high leptin and interleukin (IL)6 levels with low adiponectin simultaneously (OR = 5.03; 95% CI 1.05-24.0). High leptin levels were associated with the FDR adjusted for IgG2 Porphyromonas gingivalis, swollen joints, P gingivalis and low IL6 (OR = 2.57; 95% CI 1.14-5.95). Conclusion:High adipokine levels in eRA may modulate the disease activity. Having more than 1 adipokine at high serum levels is associated with increased disability, disease activity and BMI, indicating that RA is controlled by adiponectin levels in the early stages of the disease. High leptin levels, presence of P gingivalis and swollen joints may be the factors associated with the development of RA in FDR. K E Y W O R D Sadipokines, adiponectin, leptin, periodontitis, rheumatoid arthritis | 1991 CHAPARRO-SANABRIA et Al.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first‐degree relatives

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[ 7 – 9 ] Previous investigations have suggested that serum adipokines levels are elevated in RA patients as compared with healthy controls and are associated with disease activity. [ 10 ] However, contradictory results have been reported on the association between adipokine levels and inflammatory status in patients with AS. [ 11 ] Leptin and adiponectin have been reported to stimulate osteoblast proliferation and bone mineralization in in vitro studies [ 12 ] ; however, little attention has been directed to the role played by adipokines in the pathogenesis of new bone formation in AS.…”

Section: Introductionmentioning

confidence: 99%

Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis

et al. 2017

View full text Add to dashboard Cite

The immunomodulatory effects of adipokines have been extensively studied in rheumatic diseases, and there is a paucity of information regarding their effects on bone metabolism.The aim of this study was to investigate the relationships between serum adipokines levels and radiographic progression over 2 years in patients with ankylosing spondylitis (AS).In this preliminary longitudinal study, we prospectively recruited 20 consecutive male patients with AS and 11 gender- and age-matched healthy subjects. At the baseline and 2-year follow-up, serum adiponectin, leptin, resistin, tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and Dickkopf-1(DKK-1) levels were measured in AS patients using enzyme-linked immunosorbent assays; these measurements were only performed at the baseline for healthy controls. Radiographic progression was determined as the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) progression of ≥2 by comparing the baseline and 2-year follow-up radiographs.All AS patients were naive to TNF-α blockers at the enrollment and during the 2-year follow-up period and their median disease duration was 51.5 months. At the baseline, the serum resistin, TNF-α, and IL-6 levels were significantly higher in AS patients than in controls. At the 2-year follow-up, the median mSASSS of AS patients was found to be significantly increased from the baseline (8–10.5, P = .001) and 7 (35%) AS patients showed radiographic progression. In AS patients, the leptin and resistin levels were significantly higher at the 2-year follow-up than at the baseline. The baseline resistin levels and changes in leptin levels from the baseline to the 2-year follow-up were significantly higher in AS patients with radiographic progression than in those without radiographic progression (P = .002 and .024, respectively). The baseline resistin levels and the increase in leptin levels during the follow-up period significantly correlated with changes in mSASSS (ρ = 0.528 and 0.559, P = .017 and .01, respectively). No association between changes in serum adipokine levels and disease activity in AS patients was observed.Our findings suggest that leptin and resistin may contribute to the pathogenesis of new bone formation rather than to inflammatory processes and have the potential to be used as biomarkers of the structural outcome of AS.

show abstract

“…IL-4 drives the differentiation of T H 2 cells and IgE class switching in B cells. 6 Produced by T H 2 cells, IL-13 is involved in B-cell maturation and differentiation and eosinophil chemotaxis and is a central mediator of allergic asthma. 6 These cytokines also downregulate the expression of fundamental genes involved in skin barrier function and integrity.…”

Section: Introductionmentioning

confidence: 99%

“… 6 Produced by T H 2 cells, IL-13 is involved in B-cell maturation and differentiation and eosinophil chemotaxis and is a central mediator of allergic asthma. 6 These cytokines also downregulate the expression of fundamental genes involved in skin barrier function and integrity. 4 In addition, overexpression of IL-4 and IL-13 in AD prevents the upregulation of anti-microbial peptides in response to bacterial and viral stimuli in the skin.…”

Section: Introductionmentioning

confidence: 99%

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis

Eshtiaghi¹,

Gooderham²

2018

View full text Add to dashboard Cite

IntroductionAtopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant TH2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited.AimThis article reviews the evidence of clinical efficacy, safety, and patient-reported out-come (PRO) measures from Phase I–III trials of dupilumab in adult patients with moderate-to-severe AD.Evidence reviewResults from clinical trials of dupilumab in adults with moderate-to-severe AD have shown that weekly or biweekly dupilumab injections significantly improve clinical and PROs. Transcriptome and serum analyses also found that dupilumab significantly modulates the AD molecular signature and other TH2-associated biomarkers, compared with placebo. Additionally, concomitant use of dupilumab with topical corticosteroids (TCS) results in a greater improvement in signs and symptoms of AD than with dupilumab use alone. Throughout the trials, common adverse events were headaches, conjunctivitis, and injection site reactions. These were consistently mild–moderate and occurred with similar frequency between the treatment and placebo groups.Place in therapyIn adult patients with moderate-to-severe refractory AD, monotherapy or concomitant use of dupilumab with TCS holds great promise to significantly improve clinical outcomes and quality of life of the patient. Ongoing studies of dupilumab will help determine the clinical efficacy and safety profile of its long-term use. Finally, further economic evidence is warranted to compare the long-term costs and benefits of dupilumab with other currently available treatments for moderate-to-severe AD.

show abstract

Adipokines: role in local and systemic inflammation of rheumatic diseases

Cited by 14 publications

References 22 publications

Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first‐degree relatives

Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first‐degree relatives

Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis

Contact Info

Product

Resources

About